lapatinib has been researched along with Cardiac Toxicity in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Jackson, DB; Kim, S; Lahu, G; Lesko, LJ; Soldatos, TG; Trame, MN; Vakilynejad, M | 1 |
| Chen, X; Fu, H; Gao, Z; He, Q; Jin, Y; Luo, P; Pan, Z; Wang, X; Xu, B; Xu, Z; Yan, H; Yang, B; Yang, X; Zeng, Y; Zhang, X; Zhang, Y | 1 |
| Chattipakorn, N; Chattipakorn, SC; Leemasawat, K; Phrommintikul, A | 1 |
| Chang, MJ; Choi, HD | 1 |
| Ameels, H; Baselga, J; Berghorn, M; Borrego, MR; Bozovic-Spasojevic, I; Bradbury, I; Campbell, C; Chen, DR; de Azambuja, E; Di Cosimo, S; Ewer, M; Fumagalli, D; Harbeck, N; Huober, J; Im, YH; Izquierdo, M; Lambertini, M; Maetens, M; Piccart, M; Ponde, N; Pusztai, L; Rodeheffer, R; Suter, T; Zardavas, D | 1 |
| Tan, Q; Wei, C | 1 |
| Asif, M; Bhadauria, S; Chourasia, MK; Khanna, A; Shrivastava, R; Singh, PK; Trivedi, S | 1 |
| Cheng, AL; Hsieh, PCH; Hsu, WT; Huang, CY; Yen, CYT | 1 |
| Boswell, SA; Erickson, AR; Everley, RA; Haigis, MC; Holton, KM; Jacobson, CA; Maliszewski, L; Palmer, AC; Ringel, AE; Ron-Harel, N; Sheehan, RP; Sorger, PK; Wang, H | 1 |
| Brunelli, C; Carbone, F; Di Iorio, C; Gigli, L; Montecucco, F; Nencioni, A; Rosa, GM; Tagliasacchi, MI | 1 |
| Davoodzadeh, H; Ebadi, A; Rahmani, H; Shahriary, A; Sheikhi, MA | 1 |
4 review(s) available for lapatinib and Cardiac Toxicity
| Article | Year |
|---|---|
Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Female; Heart; Humans; Lapatinib; Molecular Targeted Therapy; Myocytes, Cardiac; Receptor, ErbB-2; Trastuzumab | 2020 |
Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; ErbB Receptors; Female; Heart; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left | 2017 |
Update on cardiotoxicity of anti-cancer treatments.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bevacizumab; Cardiotoxicity; Echocardiography; Humans; Indoles; Lapatinib; Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography; Pyrroles; Quinazolines; Radiation Injuries; Radiotherapy; Sunitinib; Taxoids; Trastuzumab; Troponin; Vinca Alkaloids | 2016 |
Applications of cardiotoxicity in breast cancer: a meta-analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Female; Humans; Lapatinib; Odds Ratio; Quinazolines; Risk; Trastuzumab; Ventricular Function, Left | 2017 |
1 trial(s) available for lapatinib and Cardiac Toxicity
| Article | Year |
|---|---|
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Topics: Aged; Biomarkers; Breast Neoplasms; Cardiotoxicity; Cardiovascular Abnormalities; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Troponin T | 2018 |
6 other study(ies) available for lapatinib and Cardiac Toxicity
| Article | Year |
|---|---|
A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development.
Topics: Cardiotoxicity; Doxorubicin; Drug Development; Drug-Related Side Effects and Adverse Reactions; Humans; Lapatinib; Paroxetine; Patient-Centered Care; Tamoxifen; Trastuzumab | 2022 |
PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Calcium; Cardiotoxicity; Endothelial Cells; Female; Heart Diseases; Humans; Induced Pluripotent Stem Cells; Lapatinib; Mice; Quinazolines; Rats; Receptor, ErbB-2; Trastuzumab | 2023 |
Comment on a meta-analysis evaluating the cardiac toxicity of lapatinib in patients with breast cancer and other HER2-positive cancers.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Female; Humans; Lapatinib; Meta-Analysis as Topic; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2018 |
Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cardiotoxicity; Cell Line, Tumor; Cell Proliferation; Chick Embryo; ErbB Receptors; Female; Humans; Lapatinib; Liposomes; Polyethylene Glycols; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2018 |
The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling.
Topics: Animals; Antineoplastic Agents; Cardiotoxicity; Disease Models, Animal; Doxorubicin; Humans; Lapatinib; Mice; Models, Biological; Myocardium; Myocytes, Cardiac; Nitric Oxide Synthase Type II; Signal Transduction | 2018 |
Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming.
Topics: Acclimatization; Antineoplastic Agents; Cardiotoxicity; Cell Differentiation; Cells, Cultured; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; Induced Pluripotent Stem Cells; Lapatinib; Myocytes, Cardiac; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Sunitinib | 2019 |